KALA BIO, Inc. (NASDAQ:KALA) Major Shareholder Bros. Advisors Lp Baker Purchases 310,559 Shares

KALA BIO, Inc. (NASDAQ:KALA) major shareholder Bros. Advisors Lp Baker purchased 310,559 shares of the company’s stock in a transaction on Monday, December 30th. The shares were purchased at an average price of $6.44 per share, with a total value of $1,999,999.96. Following the completion of the purchase, the insider now directly owns 1,083,398 shares of the company’s stock, valued at $6,977,083.12. The trade was a 40.18 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

KALA BIO Price Performance

KALA stock opened at $6.94 on Thursday. The company has a debt-to-equity ratio of 3.18, a quick ratio of 2.15 and a current ratio of 2.15. KALA BIO, Inc. has a 1 year low of $4.21 and a 1 year high of $9.25. The firm has a market cap of $31.99 million, a P/E ratio of -0.56 and a beta of -2.15. The stock has a 50-day simple moving average of $6.64 and a 200-day simple moving average of $6.25.

KALA BIO (NASDAQ:KALA) last posted its earnings results on Tuesday, November 12th. The company reported ($1.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.43) by $0.50. On average, equities analysts predict that KALA BIO, Inc. will post -10.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of KALA BIO in a research note on Friday, November 15th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in KALA BIO stock. SR One Capital Management LP purchased a new stake in KALA BIO, Inc. (NASDAQ:KALA) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO comprises 1.0% of SR One Capital Management LP’s investment portfolio, making the stock its 9th largest position. SR One Capital Management LP owned about 15.76% of KALA BIO at the end of the most recent reporting period. 24.61% of the stock is owned by institutional investors and hedge funds.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.